Utah Medical Products (UTMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Utah Medical Products

NasdaqGS•Healthcare•Medical Instruments & Supplies

$71.10+0.39(0.01%)Market closed

Market Cap

$235.81M

P/E

22.5x

P/S

6.5x

P/B

1.9x

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

How this company scores

AverageMetricSide Score: 55/100

Strongest: Balance Sheet & Red Flags (19/25); weakest: Growth (5/25).

Profitability15/25

Growth5/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality16/25

Strengths

Strong marginsLow leverageCash-backed earningsConsistent free cash flow

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 22.5x5y range 14.3x – 24.9x

Currently near its 20-quarter median.

P/S · 6.5x5y range 4.7x – 7.5x

Currently near its 20-quarter median.

P/B · 1.9x5y range 1.5x – 3.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Watch

Operating margins declined 12.2% — watch for continued compression, which may signal competitive or cost pressure.

Revenue Decline

Red Flag

Revenue declined in 7 of the last 7 quarters — persistent contraction signals a fundamental problem.

Price & Volume

Market Cap $235.81M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $36.11M
Q. Revenue: $8.53M
TTM EBITDA: $12.66M
TTM Op. Income: $10.27M
Q. Op. Income: $2.65M
TTM Net Income: $10.49M
Q. Net Income: $2.69M
EPS: $0.84
Shares Out.: $3.18M

$36.11M in TTM revenue declined 7.0% YoY, reaching $8.53M last quarter. TTM EBITDA of $12.66M and TTM operating income of $10.27M show growth is flowing through to the bottom line. TTM net income of $10.49M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 7 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 55.8%
EBITDA Margin: 33.7%
Op. Margin: 31.1%
Net Margin: 31.5%

Op. margin of 31.1% is down 1.1% YoY — costs are rising relative to revenue. Net margin at 31.5% and gross margin of 55.8% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 22.5x
P/S Ratio: 6.5x
P/B Ratio: 1.9x

At 22.5x P/E, the stock trades within typical market levels. P/S of 6.5x and P/B of 1.9x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $124.57M
Cash: $87.53M
Long-Term Debt: $195,000
Book Value: $122.03M
D/E Ratio: 0.0
Debt/EBITDA: 0.1

With $124.57M in assets and $195,000 in long-term debt, D/E is 0.0and book value is $122.03M — a conservative capital structure with a cushion to weather downturns. Across the last 6 quarters, debt/equity has fallen for 5 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.38M
TTM Free Cash Flow: $11.45M
FCF Margin: 31.7%
FCF / Net Income: 1.1

TTM FCF of $11.45M on $1.38M in operating cash flow. The FCF / Net Income ratio of 1.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.